Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGDS | O60760 | 1/20 | 0.47 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694742 | 0.88 | LMNA (0.60) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL5883141 | 0.86 | LMNA (0.58) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL7484882 | 0.85 | ALDH1A1 (0.57) | ALDH1A1LMNAKMT2AMEN1SLC6A9 | |
| Bromomethane SCHEMBL5883756 | 0.82 | LMNA (0.59) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11626488 | 0.81 | ALDH1A1 (0.74) | ALDH1A1LMNAKMT2AMEN1SLC6A9 | |
| SCHEMBL27731701 | 0.79 | HPGDS (0.62) | ALDH1A1LMNAKMT2AMEN1SLC6A9 | |
| SCHEMBL29902958 | 0.78 | LMNA (0.51) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL5787782 | 0.77 | CNR1 (0.65) | ALDH1A1LMNAKMT2AMEN1HPGDS | |
| SCHEMBL20496887 | 0.75 | ALDH1A1 (0.62) | ALDH1A1LMNAKMT2AMEN1SLC6A9 | |
| SCHEMBL24575947 | 0.74 | HPGDS (0.57) | ALDH1A1LMNAKMT2AMEN1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | claimed |
| EP-3331859-B1 | BROAD SPECTRUM REACTIVATORS OF OPNA-INHIBITION OF HUMAN CHOLINESTERASES | CENTRE NAT RECH SCIENT (FR) | 2019-10-02 | — | — | EP | disclosed |
| EP-3331859-A1 | BROAD SPECTRUM REACTIVATORS OF OPNA-INHIBITION OF HUMAN CHOLINESTERASES | Centre National De La Recherche Scientifique (FR) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021319-A1 | BROAD SPECTRUM REACTIVATORS OF OPNA-INHIBITION OF HUMAN CHOLINESTERASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2017-02-09 | — | — | WO | disclosed |
| US-8729107-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-8097638-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2011-06-02 | — | — | US | disclosed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | P2RY4, INA, PMP22 | ALDH1A1 298/4885LMNA 2385/4885KMT2A 1451/4885 |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PMP22, SMN1; SMN2, MUSK | ALDH1A1 256/4885LMNA 2624/4885KMT2A 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.